Healthcare
Oncoinvent has reported encouraging interim safety data for Radspherin, its targeted radiation therapy administered into the abdomen following surgery for advanced ovarian cancer. Of the 74 patients randomised by 30 October, 56 were included in the safety analysis, comprising 40 receiving Radspherin and 16 receiving standard care alone. No serious adverse events were considered possibly related to Radspherin, and there were no deaths or treatment discontinuations due to adverse events. Five Radspherin recipients (12.5%) experienced 10 possibly related adverse events, all mild or moderate, while the overall incidence of adverse events was similar between the treatment groups. Encouragingly, following its review, the independent monitoring committee recommended that the trial continue without modification.
The findings reinforce Radspherin’s favourable safety profile observed in earlier trials and support Oncoinvent’s preparations for Phase III development. Radspherin aims to eliminate microscopic cancer deposits remaining after surgery, although its ability to delay disease progression remains to be established in a randomised setting. The next important catalyst is the interim efficacy readout expected in April 2027, with Phase II recruitment scheduled for completion in the first half of 2027.
Industrials | Comment
Industrials | Comment
Investment Companies | Comment
Industrials | Comment